Co-expression of CD30 and SLFN11 serves as a dual biomarker for the treatment of cutaneous T-cell lymphoma.
Saved in:
| Title: | Co-expression of CD30 and SLFN11 serves as a dual biomarker for the treatment of cutaneous T-cell lymphoma. |
|---|---|
| Authors: | Shimauchi T; Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan., Murai J; Division of Cell Growth and Tumor Regulation, Proteo-Science Center, Toon, Ehime, 791-0295, Japan.; Department of Biochemistry and Molecular Genetics, Ehime University Graduate School of Medicine, Toon, Ehime, 791-0295, Japan., Iwasaki M; Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan., Phadungsaksawasdi P; Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan., Ojima T; Department of Community Health and Preventive Medicine, Hamamatsu University School of Medicine, Hamamatsu, 431-3192 Japan., Fujii K; Department of Dermatology, Kindai University Hospital, Osaka, 589-8511, Japan., Honda T; Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan. |
| Source: | NAR cancer [NAR Cancer] 2025 Oct 07; Vol. 7 (4), pp. zcaf037. Date of Electronic Publication: 2025 Oct 07 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101769553 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-8674 (Electronic) Linking ISSN: 26328674 NLM ISO Abbreviation: NAR Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2632-8674 |
|---|---|
| DOI: | 10.1093/narcan/zcaf037 |
